Review Article| Volume 22, ISSUE 1, P2-11, March 2023

Download started.


Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

Published:November 04, 2022DOI:


      Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year overall survival of 11%. The disease is usually diagnosed at advanced stages, and systemic chemotherapy is the standard-of-care treatment for the majority of patients with PDAC. Although novel treatment options, such as targeted therapy and immunotherapy, have achieved substantial progress leading to practice-changing results, with FDA approvals for several solid tumors so far, the progress achieved for PDAC is relatively limited. Recent studies uncovered potential therapeutic targets for patients with PDAC, and potential therapeutic opportunities are currently being further examined. Herein, we review recent advances in systemic therapy regimens, including cytotoxic agents, targeted therapies, immunotherapy, and novel therapeutic options for managing patients with PDAC. We also elaborate on molecular profiling to guide treatment and existing therapeutic opportunities that may further advance the clinical care of patients with this devastating disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A.
        Cancer statistics.
        CA Cancer J Clin. 2022; 72: 7-33
        • Quante AS
        • Ming C
        • Rottmann M
        • et al.
        Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.
        Cancer Med. 2016; 5: 2649-2656
        • Kamisawa T
        • Wood LD
        • Itoi T
        • Takaori K.
        Pancreatic cancer.
        Lancet North Am Ed. 2016; 388: 73-85
        • Sahin IH
        • Iacobuzio-Donahue CA
        • O'Reilly EM
        Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
        Expert Opin Ther Targets. 2016; 20: 341-359
        • Sahin IH
        • Askan G
        • Hu ZI
        • O'Reilly EM
        Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?.
        Ann Oncol. 2017; 28: 2950-2961
        • Blackford A
        • Serrano OK
        • Wolfgang CL
        • et al.
        SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
        Clin Cancer Res. 2009; 15: 4674-4679
        • Jeong J
        • Park YN
        • Park JS
        • Yoon D-S
        • Chi HS
        • Kim BR.
        Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
        Yonsei Med J. 2005; 46: 519-525
        • Hu ZI
        • Shia J
        • Stadler ZK
        • et al.
        Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations.
        Clin Cancer Res. 2018; 24: 1326-1336
        • Conroy T
        • Desseigne F
        • Ychou M
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825
        • Von Hoff DD
        • Ervin T
        • Arena FP
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703
        • Chun JW
        • Lee SH
        • Kim JS
        • et al.
        Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
        BMC Cancer. 2021; 21: 537
        • Nevala-Plagemann C
        • Hidalgo M
        • Garrido-Laguna I.
        From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
        Nat Rev Clin Oncol. 2020; 17: 108-123
        • Ahn DH
        • Krishna K
        • Blazer M
        • et al.
        A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
        Therap Adv Med Oncol. 2017; 9: 75-82
        • Wattenberg MM
        • Asch D
        • Yu S
        • et al.
        Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
        Br J Cancer. 2020; 122: 333-339
        • O'Reilly EM
        • Lee JW
        • Zalupski M
        • et al.
        A randomized, multicenter, phase II trial of gemcitabine (G) , cisplatin (C)+/-veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g) BRCA/PALB2 mutation.
        Am Soc Clin Oncol. 2020;
        • Wang-Gillam A
        • Li C-P
        • Bodoky G
        • et al.
        Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
        Lancet North Am Ed. 2016; 387: 545-557
        • Glassman DC
        • Palmaira RL
        • Covington CM
        • et al.
        Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
        BMC Cancer. 2018; 18: 1-10
        • Zaanan A
        • Trouilloud I
        • Markoutsaki T
        • et al.
        FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.
        BMC Cancer. 2014; 14: 1-8
        • Aguirre AJ
        • Nowak JA
        • Camarda ND
        • et al.
        Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.
        Cancer Discov. 2018; 8: 1096-1111
        • Pishvaian MJ
        • Blais EM
        • Brody JR
        • et al.
        Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
        Lancet Oncol. 2020; 21: 508-518
        • Sahin IH
        • Lowery MA
        • Stadler ZK
        • et al.
        Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
        Expert Rev Gastroenterol Hhepatol. 2016; 10: 893-905
        • Pishvaian MJ
        • Blais EM
        • Brody JR
        • et al.
        Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program.
        JCO Precis Oncol. 2019; 3: 1-10
        • Park W
        • Chen J
        • Chou JF
        • et al.
        Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selectiongenomic methods identify HRD and benefit to platinum in PDAC.
        Clin Cancer Res. 2020; 26: 3239-3247
        • O'Reilly EM
        • Lee JW
        • Zalupski M
        • et al.
        Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation.
        J Clin Oncol. 2020; 38: 1378
        • Teo MY
        • O'Reilly EM.
        Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?.
        J Gastrointest Oncol. 2016; 7: 738
        • Golan T
        • Hammel P
        • Reni M
        • et al.
        Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
        N Engl J Med. 2019; 381: 317-327
        • Reiss KA
        • Mick R
        • O'Hara MH
        • et al.
        Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2.
        J Clin Oncol. 2021; 39: 2497-2505
        • Carlson RW
        • Koh W-J.
        The NCCN 2022 annual conference.
        J Natil Comprehensive Cancer Network. 2022; 20: 549-550
        • Reiss KA
        • Mick R
        • Teitelbaum U
        • et al.
        Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
        Lancet Oncol. 2022; 23: 1009-1020
        • Skoulidis F
        • Li BT
        • Dy GK
        • et al.
        Sotorasib for lung cancers with KRAS p.G12C mutation.
        N Engl J Med. 2021; 384: 2371-2381
        • Waters AM
        • Der CJ.
        KRAS: the critical driver and therapeutic target for pancreatic cancer.
        Cold Spring Harb Perspect Med. 2018; 8
        • Luchini C
        • Paolino G
        • Mattiolo P
        • et al.
        KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
        J Exp Clin Cancer Res. 2020; 39: 227
        • Dreyer SB
        • Chang DK
        • Bailey P
        • Biankin AV.
        Pancreatic cancer genomes: implications for clinical management and therapeutic development.
        Clin Cancer Res. 2017; 23: 1638-1646
        • Strickler JH
        • Satake H
        • Hollebecque A
        • et al.
        First Data for Sotorasib in Patients With Pancreatic Cancer With KRAS P. G12C Mutation: A Phase I/II Study Evaluating Efficacy And Safety.
        American Society of Clinical Oncology, 2022
        • Bekaii-Saab TS
        • Spira AI
        • Yaeger R
        • et al.
        KRYSTAL-1: Updated Activity and Safety of Adagrasib (MRTX849) in Patients (Pts) With Unresectable or Metastatic Pancreatic Cancer (PDAC) and Other Gastrointestinal (GI) Tumors Harboring A KRASG12C Mutation.
        American Society of Clinical Oncology, 2022
        • Gustafson WC
        • Wildes D
        • Rice MA
        • et al.
        Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.
        J Clin Oncol. 2022; 40 (591-591)
        • Gort E
        • Johnson ML
        • Hwang JJ
        • et al.
        A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
        J Clin Oncol. 2020; 38: TPS3651
      1. Christensen JG. Discovery and characterization of MRTX1133, a selective non-covalent inhibitor of KRASG12D. Paper presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics: Virtual; 2021.

        • Pant S
        • Furqan M
        • Abdul-Karim RM
        • et al.
        First-In-Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)-Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors.
        Journal of Clinical Oncology. 2022; 40: TPS2701
        • Leidner R
        • Sanjuan Silva N
        • Huang H
        • et al.
        Neoantigen T-cell receptor gene therapy in pancreatic cancer.
        N Engl J Med. 2022; 386: 2112-2119
        • Hofmann MH
        • Gerlach D
        • Misale S
        • Petronczki M
        • Kraut N.
        Expanding the reach of precision oncology by drugging All KRAS mutants.
        Cancer Discov. 2022; 12: 924-937
        • Gower A
        • Golestany B
        • Gong J
        • Singhi AD
        • Hendifar AE.
        Novel ALK fusion, PPFIBP1-ALK, in pancreatic ductal adenocarcinoma responsive to alectinib and lorlatinib.
        JCO Precision Oncology. 2020; 4: 865-870
        • Philip PA
        • Azar I
        • Xiu J
        • et al.
        Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma.
        Clin Cancer Res. 2022; 28: 2704-2714
        • Fusco MJ
        • Saeed-Vafa D
        • Carballido EM
        • et al.
        Identification of targetable gene fusions and structural rearrangements to foster precision medicine in KRAS wild-type pancreatic cancer.
        JCO Precision Oncology. 2021; 5: 65-74
        • Prall OWJ
        • Nastevski V
        • Xu H
        • et al.
        RAF1 rearrangements are common in pancreatic acinar cell carcinomas.
        Mod Pathol. 2020; 33: 1811-1821
        • McEvoy CR
        • Kee D
        • Prall OWJ
        • et al.
        MEK inhibitor therapy in carcinomas with RAF1 fusions: inferior response in a patient with pancreatic acinar cell carcinoma.
        JCO Precision Onco. 2019; 3: 1-2
        • Ayasun R
        • Guven DC
        • Gullu I.
        A novel agnostic tumor: NTRKoma.
        J Oncol Pharm Pract. 2021; 27: 802-803
        • Pishvaian MJ
        • Rolfo CD
        • Liu SV
        • Multani PS
        • Chow Maneval E
        • Garrido-Laguna I
        Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic Cancer Who Harbor NTRK and ROS1 Fusions.
        American Society of Clinical Oncology, 2018
        • Heining C
        • Horak P
        • Uhrig S
        • et al.
        NRG1 fusions in KRAS wild-type pancreatic cancerNRG1 fusions in KRAS wild-type pancreatic cancer.
        Cancer Discov. 2018; 8: 1087-1095
        • Schram AM
        • Odintsov I
        • Espinosa-Cotton M
        • et al.
        Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangementsTargeting cancers with NRG1 rearrangements.
        Cancer Discov. 2022; 12: 1233-1247
        • Luchini C
        • Brosens LAA
        • Wood LD
        • et al.
        Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
        Gut. 2021; 70: 148-156
        • O'Reilly EM
        • Oh DY
        • Dhani N
        • et al.
        Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.
        JAMA Oncol. 2019; 5: 1431-1438
        • O'Reilly EM
        • Oh D-Y
        • Dhani N
        • et al.
        Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.
        JAMA Oncol. 2019; 5: 1431-1438
        • Renouf D
        • Knox J
        • Kavan P
        • et al.
        LBA65 The Canadian Cancer Trials Group PA. 7 trial:rResults of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
        Ann Oncol. 2020; 31: S1195
        • Ko AH
        • Lee J
        • ALSINA M
        • et al.
        Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
        Journal of Clinical Oncology. 2020; 38: 4540
        • Parikh AR
        • Szabolcs A
        • Allen JN
        • et al.
        Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.
        Nat Cancer. 2021; 2: 1124-1135
        • Tang K
        • Wu Y-H
        • Song Y
        • Yu B.
        Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
        J Hematol Oncol. 2021; 14: 1-21
        • Fox E
        • Oliver T
        • Rowe M
        • et al.
        Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer.
        Front Oncol. 2018; 8: 370
        • Wan Z
        • Sun J
        • Xu J
        • et al.
        Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
        Acta Biomater. 2019; 90: 300-313
        • Bahary N
        • Wang-Gillam A
        • Haraldsdottir S
        • et al.
        Phase 2 Trial of the IDO Pathway Inhibitor Indoximod Plus Gemcitabine/Nab-Paclitaxel for the Treatment of Patients With Metastatic Pancreas Cancer.
        American Society of Clinical Oncology, 2018
        • Hu ZI
        • Bendell JC
        • Bullock A
        • et al.
        A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
        Cancer Med. 2019; 8: 5148-5157
        • Dotan E
        • Cardin DB
        • Lenz H-J
        • et al.
        Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
        Journal of Clinical Oncology. 2019; 37: 369
        • Huang H
        • Brekken RA.
        The next wave of stroma-targeting therapy in pancreatic cancer.
        Cancer Res. 2019; 79: 328-330
        • Uzunparmak B
        • Sahin IH.
        Pancreatic cancer microenvironment: a current dilemma.
        Clin Transl Med. 2019; 8
        • Catenacci DV
        • Junttila MR
        • Karrison T
        • et al.
        Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer.
        J Clin Oncol. 2015; 33: 1-8
        • Madden J.
        Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer.
        Infin Pharm. 2012;
        • Ramanathan RK
        • McDonough SL
        • Philip PA
        • et al.
        Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313.
        J Clin Oncol. 2019; 37: 1062
        • Tempero MA
        • Van Cutsem E
        • Sigal D
        • et al.
        HALO 109-301: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Pegvorhyaluronidase Alfa (PEGPH20)+ Nab-Paclitaxel/Gemcitabine (AG) in Patients (pts) With Previously Untreated Hyaluronan (HA)-High Metastatic Pancreatic Ductal Adenocarcinoma (mPDA).
        American Society of Clinical Oncology, 2020
        • Askan G
        • Sahin IH
        • Chou JF
        • et al.
        Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
        BMC Cancer. 2021; 21: 1-11
        • Sahin I
        • Askan G
        • Hu Z
        • O'Reilly E
        Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?.
        Ann Oncol. 2017; 28: 2950-2961
        • Sahin IH
        • Akce M
        • Alese O
        • et al.
        Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
        Br J Cancer. 2019; 121: 809-818
        • Datta J
        • Bianchi A
        • De Castro
        • Silva I
        • et al.
        Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
        Oncogene. 2022; 41: 3640-3654
        • Gu M
        • Gao Y
        • Chang P.
        KRAS mutation dictates the cancer immune environment in pancreatic ductal adenocarcinoma and other adenocarcinomas.
        Cancers. 2021; 13: 2429
        • Ahmed S
        • Bradshaw A-D
        • Gera S
        • Dewan MZ
        • Xu R.
        The TGF-β/Smad4 signaling pathway in pancreatic carcinogenesis and its clinical significance.
        J Clin Med. 2017; 6: 5
        • Newsted D
        • Banerjee S
        • Watt K
        • et al.
        Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models.
        Oncoimmunology. 2019; 8e1539613
        • Park W
        • O'Reilly EM
        • Furuse J
        • Kunieda F
        • Jie F
        • Kindler HL.
        Phase II, Open-Label, Randomized Study of First-Line Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel (GN) in Claudin 18.2–Positive Metastatic Pancreatic Cancer (mPC).
        American Society of Clinical Oncology, 2020